Header
For Healthcare Professionals
SPEVIGO® Logo
Interior_Pages_Hero

Dosing and administration

The recommended dose of SPEVIGO® is a single continuous IV infusion of 900 mg administered over 90 minutes1

If flare symptoms persist, an additional IV infusion may be administered 1 week after the initial dose.1

Dosing_Graphic

*Pustular clearance defined as GPPGA pustulation subscore of 0 (no visible pustules).1

†Flare control defined as GPPGA total score ≤1 and was reported for the 12-week study.3

‡Flare persistence defined as GPPGA total score ≥2 and GPPGA pustulation subscore ≥2.3

GPP=Generalized Pustular Psoriasis; GPPGA=Generalized Pustular Psoriasis Physician Global Assessment; IV=intravenous.

References

  1. SPEVIGO® Prescribing Information, Singapore

  2. Choon SE, Lebwohl MG, Marrakchi S, et al. Study protocol of the global Effisayil 1 phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open. 2021;11(3):e043666. doi:10.1136/bmjopen-2020-043666

  3. Bachelez H, Choon SE, Marrakchi S, et al; for the Effisayil 1 Trial Investigators. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431-2440. doi:10.1056/NEJMoa2111563